- Home
- WINT vs VLCN Comparison
WINT vs VLCN Comparison
Compare WINT & VLCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- VLCN
- Stock Information
- Founded
- WINT 1992
- VLCN 2020
- Country
- WINT United States
- VLCN United States
- Employees
- WINT N/A
- VLCN N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- VLCN Auto Manufacturing
- Sector
- WINT Health Care
- VLCN Consumer Discretionary
- Exchange
- WINT Nasdaq
- VLCN Nasdaq
- Market Cap
- WINT 2.0M
- VLCN 1.9M
- IPO Year
- WINT 1995
- VLCN 2021
- Fundamental
- Price
- WINT $0.12
- VLCN $1.86
- Analyst Decision
- WINT Hold
- VLCN
- Analyst Count
- WINT 1
- VLCN 0
- Target Price
- WINT $7.00
- VLCN N/A
- AVG Volume (30 Days)
- WINT 7.3M
- VLCN 2.7M
- Earning Date
- WINT 11-27-2024
- VLCN 03-27-2025
- Dividend Yield
- WINT N/A
- VLCN N/A
- EPS Growth
- WINT N/A
- VLCN N/A
- EPS
- WINT N/A
- VLCN N/A
- Revenue
- WINT N/A
- VLCN $4,134,075.00
- Revenue This Year
- WINT N/A
- VLCN $339.16
- Revenue Next Year
- WINT N/A
- VLCN N/A
- P/E Ratio
- WINT N/A
- VLCN N/A
- Revenue Growth
- WINT N/A
- VLCN 41.15
- 52 Week Low
- WINT $0.11
- VLCN $3.18
- 52 Week High
- WINT $14.75
- VLCN $2,792.00
- Technical
- Relative Strength Index (RSI)
- WINT 15.60
- VLCN 30.47
- Support Level
- WINT $0.21
- VLCN $3.18
- Resistance Level
- WINT $0.33
- VLCN $3.60
- Average True Range (ATR)
- WINT 0.03
- VLCN 0.73
- MACD
- WINT 0.00
- VLCN -0.01
- Stochastic Oscillator
- WINT 2.15
- VLCN 1.99
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About VLCN Volcon Inc. Common stock
Volcon Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use. The company has hundred and three dealers covering twenty eight states.